First Allied Advisory Services’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

First Allied Advisory Services’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-6,550	Closed	-$203K	–	1572
2017 Q3	$203K	Buy	+6,550	New	+$197K	0.01%	1015

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

First Allied Advisory Services's RETA Position: Q4 2017 in Review

First Allied Advisory Services sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2017, closing a stake of 6,550 shares — an estimated $203K sold.

First Allied Advisory Services first reported a position in RETA in Q3 2017 and held it in 1 quarter. The position peaked at $203K in Q3 2017. 89 funds tracked by Wall St. Rank hold RETA as of Q4 2017.

First Allied Advisory Services reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2017 after selling out during the quarter.
First Allied Advisory Services sold 6,550 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2017, an estimated $203K.
First Allied Advisory Services first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 1 quarter.
First Allied Advisory Services's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $203K in Q3 2017.
89 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2017.

Based on First Allied Advisory Services's 13F filing for Q4 2017, filed 8 Feb 2018.